Baird analyst Eric Coldwell lowered the firm’s price target on Medpace (MEDP) to $313 from $340 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and although they are not negative on the shares, they are not overly excited as Bookings remain in “show-me” mode.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace Holdings: Hold Rating Amid Mixed Financial Results and Demand Concerns
- Medpace Holdings Reports Strong Q1 2025 Results
- Medpace Holdings Inc. Earnings Call: Mixed Sentiments and Modest Growth
- Medpace downgraded to Market Perform at William Blair amid uncertainty
- Medpace downgraded to Market Perform from Outperform at William Blair